MYCN and neuroblastoma: ABT-199 has exhibited a relatively favorable toxicity profile (Seymour et al., 2014, Ma et al., 2014), and it uniquely induced apoptosis in MYCN-amplified neuroblastoma cells (Figures 3B and S3A); we therefore decided to pursue the drug as part of a combination targeted therapy strategy for MYCN-amplified neuroblastoma.